Identification of people with heterozygous familial hypercholesterolemia

被引:49
|
作者
Haase, Annie [1 ]
Goldberg, Anne C. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
cascade screening; familial hypercholesterolemia; genetic testing; universal screening; ASSOCIATION EXPERT PANEL; CHOLESTEROL-LOWERING TREATMENT; RECOMMENDATIONS; DIAGNOSIS; MANAGEMENT; CHILDREN; ADULTS; HEALTH;
D O I
10.1097/MOL.0b013e3283556c33
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review Familial hypercholesterolemia is an underdiagnosed autosomal codominant genetic condition associated with significantly increased risk of early cardiovascular disease when untreated. Early diagnosis and treatment decrease the excess risk, and strategies for identification of affected individuals are being developed worldwide. This review will discuss, from a clinician's perspective, some of the issues involved in identifying people with familial hypercholesterolemia. Recent findings Several sets of recommendations have been published outlining the strategies for identification of people with familial hypercholesterolemia in various countries and regions. These include Australasia, Europe, and the USA. Summary Continuing efforts to find the best methods for identification of people with familial hypercholesterolemia are needed to ensure that this very treatable inherited condition is diagnosed early enough to prevent the development of atherosclerotic vascular disease.
引用
收藏
页码:282 / 289
页数:8
相关论文
共 50 条
  • [31] Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
    Santos, Raul D.
    Wiegman, Albert
    Caprio, Sonia
    Cariou, Bertrand
    Averna, Maurizio
    Poulouin, Yann
    Scemama, Michel
    Manvelian, Garen
    Garon, Genevieve
    Daniels, Stephen
    JAMA PEDIATRICS, 2024, 178 (03) : 283 - 293
  • [32] Mortality from heterozygous familial hypercholesterolemia.
    Sijbrands, EJG
    Defesche, JC
    Lombardi, P
    Westendorp, RJG
    Smelt, AHM
    Kastelein, JJP
    CIRCULATION, 1996, 94 (08) : 4321 - 4321
  • [33] Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
    Civeira, F
    ATHEROSCLEROSIS, 2004, 173 (01) : 55 - 68
  • [34] DIFFERENT PHENOTYPES IN SIBLINGS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Kyselak, O.
    Soska, V.
    ATHEROSCLEROSIS, 2018, 275 : E182 - E182
  • [35] Genetic screening for homozygous and heterozygous familial hypercholesterolemia
    Izar, Maria C.
    Machado, Valeria A.
    Fonseca, Francisco A.
    APPLICATION OF CLINICAL GENETICS, 2010, 3 : 147 - 157
  • [36] Phenotypical features of a heterozygous form of familial hypercholesterolemia
    Malyshev, P. P.
    Rozhkova, T. A.
    Solovyeva, E. Yu.
    Meshkov, A. N.
    Kaminnaya, V. I.
    Kukharchuk, V. V.
    TERAPEVTICHESKII ARKHIV, 2007, 79 (09) : 34 - 38
  • [37] Clinical management of Heterozygous Familial Hypercholesterolemia (FH)
    Soran, H.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 41 - 41
  • [38] Lipoprotein(a) metabolism in patients with heterozygous familial hypercholesterolemia
    Parhofer, KG
    Ritter, MM
    Geiss, C
    Schwandt, P
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 146 - 146
  • [39] Disparities in Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
    Shustak, Rachel
    Perlstein, Abigail
    Artis, Amanda
    Zavez, Alexis
    Tam, Vicky
    Martino, Giordana
    Brothers, Julie
    CIRCULATION, 2024, 150
  • [40] Heterozygous familial hypercholesterolemia: prevalence and control rates
    Polychronopoulos, Georgios
    Tzavelas, Marios
    Tziomalos, Konstantinos
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2021, 16 (04) : 175 - 179